Perez-Fidalgo JA - Search Results

1

Integrating radical local treatment of the primary in the management of stage IV breast cancer. When is the best moment for the resection of the primary tumor?

Perez-Fidalgo JA, Caballero A, Lluch A. Perez-Fidalgo JA, et al. Eur J Surg Oncol. 2012 Aug;38(8):643-4. doi: 10.1016/j.ejso.2012.03.003. Epub 2012 Apr 5. Eur J Surg Oncol. 2012. PMID: 22483703 No abstract available.

2

Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?

Pérez-Fidalgo JA, Pimentel P, Caballero A, Bermejo B, Barrera JA, Burgues O, Martinez-Ruiz F, Chirivella I, Bosch A, Martínez-Agulló A, Lluch A. Pérez-Fidalgo JA, et al. Breast. 2011 Dec;20(6):548-54. doi: 10.1016/j.breast.2011.06.005. Epub 2011 Aug 3. Breast. 2011. PMID: 21816613 Free article.

3

Parotid gland metastasis of a breast cancer.

Perez-Fidalgo JA, Chirivella I, Laforga J, Colio JM, Blanes MD, Baydal R, Roselló S, De-la-Morena E, Lluch A. Perez-Fidalgo JA, et al. Clin Transl Oncol. 2007 Apr;9(4):264-5. doi: 10.1007/s12094-007-0051-2. Clin Transl Oncol. 2007. PMID: 17462982

4

Zoledronic acid in the treatment of metastatic breast cancer.

Lluch A, Cueva J, Ruiz-Borrego M, Ponce J, Pérez-Fidalgo JA. Lluch A, et al. Anticancer Drugs. 2014 Jan;25(1):1-7. doi: 10.1097/CAD.0000000000000020. Anticancer Drugs. 2014. PMID: 24100278 Review.

5

Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain).

Pérez-Fidalgo JA, Miranda J, Chirivella I, Ibáñez J, Bermejo B, Pons C, Melchor I, Santaballa A, Martínez-Ruiz F, Lluch A, Salas D. Pérez-Fidalgo JA, et al. Clin Transl Oncol. 2008 Nov;10(11):745-52. doi: 10.1007/s12094-008-0281-y. Clin Transl Oncol. 2008. PMID: 19015071

6

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.

Pérez-Fidalgo JA, Eroles P, Ferrer J, Bosch A, Burgués O, Martínez F, Bermejo B, Lluch A, González-Angulo AM. Pérez-Fidalgo JA, et al. Breast. 2013 Oct;22(5):974-9. doi: 10.1016/j.breast.2013.05.014. Epub 2013 Jun 25. Breast. 2013. PMID: 23809906

7

Emerging EGFR antagonists for breast cancer.

Lluch A, Eroles P, Perez-Fidalgo JA. Lluch A, et al. Expert Opin Emerg Drugs. 2014 Jun;19(2):165-81. doi: 10.1517/14728214.2014.903919. Epub 2014 May 15. Expert Opin Emerg Drugs. 2014. PMID: 24831079 Review.

8

Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Eroles P, et al. Cancer Treat Rev. 2012 Oct;38(6):698-707. doi: 10.1016/j.ctrv.2011.11.005. Epub 2011 Dec 16. Cancer Treat Rev. 2012. PMID: 22178455 Review.

9

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.

Pérez-Fidalgo JA, Bermejo B, Chirivella I, Martínez MT, González I, Cejalvo JM, Catoira I, Martínez P, Contel E, Lluch A. Pérez-Fidalgo JA, et al. Clin Transl Oncol. 2014 Sep;16(9):814-22. doi: 10.1007/s12094-013-1153-7. Epub 2014 Feb 15. Clin Transl Oncol. 2014. PMID: 24532305 Free PMC article.

10

Concordance of genomic alterations between primary and recurrent breast cancer.

Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Meric-Bernstam F, et al. Mol Cancer Ther. 2014 May;13(5):1382-9. doi: 10.1158/1535-7163.MCT-13-0482. Epub 2014 Mar 7. Mol Cancer Ther. 2014. PMID: 24608573 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters